Pα+ Psychedelic Bulletin #221: Helus Reports Murky Phase 2a Results; AtaiBeckley Says R-MDMA Met Safety Goal in SAD, Details Phase 3 Design for 5-MeO-DMT in TRD; Psilocybin for Smoking Cessation Study Published

Last Thursday, Helus Pharma (formerly Cybin) quietly announced topline results from its Phase 2 study (n=36) of its intramuscular (IM) deuterated DMT analog (HLP004) in generalised anxiety disorder (GAD). As a reminder, participants received two doses of either 20 mg or 2 mg of the study drug three weeks apart, as an adjunct to standard of care treatments. (It is currently unclear what non-study…

Source